AmpC is a group I, class C -lactamase present in most Enterobacteriaceae and in Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli. The β-lactam class of antibiotics is one of the most important structural classes of antibacterial compounds and act by inhibiting the bacterial D ,D -transpeptidases that are responsible for the final step of peptidoglycan cross-linking. Our main aim in the study is to screen possible inhibitors against AmpC / β -lactamase (an enzyme responsible for antimicrobial activity in Pseudomonas aeruginosa), through virtual screening of 1364 NCI (National Cancer Institute) diversity set II compounds. Homology Model of AmpC / β -lactamase was constructed using MODELLER and the Model was validated using PROCHECK and Verify 3D programs to obtain a stable structure, which was further used for virtual screening of NCI (National Cancer Institute) diversity set II compounds through molecular Docking studies using Autodock. The amino acid sequence of the β -lactamase was also subjected to ScanProsite web server to find any pattern present in the sequence. After the prediction of 3-dimensional model of AmpC/ β-lactamase, the possible Active sites of β -lactamase were determined using LIGSITE csc and CastP web servers simultaneously. The Docked complexes were validated and Enumerated based on the Autodock Scoring function to pick out the best inhibitor based on Autodock energy score. Thus from the entire 1364 NCI diversity set II compounds which were Docked, the best four docking solutions were selected (ZINC12670903, ZINC17465965, ZINC11681166 and ZINC13099024). Further the Complexes were analyzed through LIGPLOT for their interaction for the 4 best docked NCI diversity set II compounds. Thus from the Complex scoring and binding ability it is deciphered that these NCI diversity set II compounds could be promising inhibitors for Pseudomonas aeruginosa using AmpC / β -lactamase as Drug target yet pharmacological studies have to confirm it.
Background:
Pseudomonas aeruginosa is an opportunistic pathogen, meaning that it exploits some break in the host defenses to initiate an infection. In fact, Pseudomonas aeruginosa is the epitome of an opportunistic pathogen of humans. The bacterium almost never infects uncompromised tissues, yet there is hardly any tissue that it cannot infect if the tissue defenses are compromised in some manner. It causes urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections and a variety of systemic infections, particularly in patients with severe burns and in cancer and AIDS patients who are immunosuppressed. Pseudomonas aeruginosa infection is a serious problem in patients hospitalized with cancer, cystic fibrosis, and burns. The case fatality rate in these patients is near 50 percent. [1, 2, 3]. Pseudomonas aeruginosa is intrinsically resistant to many antibiotics, or can develop resistance during treatment with consequent high mortality, and is, increasingly, a cause of infection in immunocompromised patients. The most relevant mechanism for the development of resistance to the antipseudomonal penicillins (such as ticarcillin or piperacillin) and cephalosporins (such as ceftazidime) is the selection of mutations leading to the hyperproduction of the chromosomal cephalosporinase AmpC [4, 5, 6]. AmpC is a group I, class C -lactamase present in most Enterobacteriaceae and in P. aeruginosa and other nonfermenting gramnegative bacilli [7, 8] . The β-lactam class of antibiotics is one of the most important structural classes of antibacterial compounds and act by inhibiting the bacterial D ,D -transpeptidases that are responsible for the final step of peptidoglycan cross-linking. The resistance mechanism in bacteria to β -lactams is the production of β-lactamases that catalyze the hydrolysis of the β -lactam ring, preventing their interaction with the D,D-transpeptidases. During treatment with lactams, resistant mutants showing constitutive high levels of AmpC production are frequently selected, leading to therapeutic failure [9] . Thus due to emergence of multidrug resistant and extremely drug resistant strains of Pseudomonas aeruginosa makes searching for drugs that are effective against these strains imperative.
Our main aim in the study is to screen possible inhibitors against AmpC / β -lactamase (an enzyme responsible for antimicrobial activity in Pseudomonas aeruginosa), through virtual screening of 1364 NCI (National Cancer Institute) diversity set II compounds. NCI Diversity Set II is a collection of 1,364 compounds chosen (from 140,000 open compounds in the NCI chemical repository with more than or equal to 250 mg inventory) to cover a large, diverse range of molecular scaffolds and pharmacophore features, while also being relatively rigid. All compounds in the Diversity Set II have five or fewer rotatable bonds, facilitating pharmacophore development and conformational sampling [10].
Methodology: Comparative modeling of AmpC / β -lactamase
As the tertiary structure of AmpC/ β-lactamase is not available in the structure databases the structure was predicted by comparative modelling approach. The comparative modelling of P. aeruginosa βlactamase was done using MODELLER 9v6 [11] and five models were generated. The peptide sequence of P. aeruginosa β-lactamase was retrieved from UniProt Knowledge Base, http://www.uniprot.org, (UniProt acc. No. P24735), ranging from 27 to 397 residues. ClustalW was used to produce alignment between the P. aeruginosa βlactamase sequence and the sequence of the templates (PDB: 2QZ6 and 1ZKJ) chosen from PDB BLAST hit. The predicted 3-D structures were evaluated using the PROCHECK 
Visualization:
All the visualization of the structure files were done using PyMol molecular graphics system [20] .
Discussion:
The hypothetical protein models generated in the modeling procedure were analyzed online by submitting to NIH MBI Laboratory for Structural Genomics and Proteomics' SAVES server. Validity reports generated by PROCHECK and Verfiy_3D judged accuracy of the protein models. A comparison of the results obtained from the abovementioned validation tools, showed that one of the models generated by Modeller is more acceptable in comparison to the others and was selected for further studies. For the final selected model Ramachandran plot generated by PROCHECK showed 95.1% residues in the most favored region (Figure 1) . The compatibility of the atomic model (3D) with its own amino acid sequence (1D) computed by Verfy_3D reported 100.00% of the residues having an average 3D-1D score > 0.2 .
After the validation, the sequence of the β -lactamase was scanned for any pattern present in the sequence using ScanProsite. The regular expression generated by the scan (
[FY] -E -[LIVM] -G -S -[LIVMG]
-[SA] -K ) suggested β -lactamase class-C active site region with first Serine residue as the catalytic residue. Active sites in the modeled protein structure were detected using LIGSITE csc and CastP webserver. The LIGSITE csc and CastP programs detected all the possible pockets in the structure which were compared with active site location from the homologous structures complexed with the substrates available in the PDB. Residues within the 5 A radius of the coordinates of the center of the active site detected by the LIGSITE csc was also studied for the catalytic Serine residue as well as other residues found conserved in the ScanProsite. The various pockets obtained by the CastP program were also looked for the conserved residues and the spatial location of the pockets found by the program, the 2 nd pocket detected was found better in all respects hence it was chosen as the most biologically favorable site for Docking study and other Identified Active sites were neglected (Figure 2) .
A set of 1364 compounds available in NCI Diversity Set II were obtained from ZINC database in mol2 format, the individual mol2 files converted into pdbqt file supported by Autodock4 using the python script prepare_ligand4.py available in Autodock Tools package. The receptor molecule was also converted into pdbqt format using prepare_receptor4.py script of Autodock Tools. The coordinates generated by the Ligsite in the grid parameter file, the grid was generated using Autogrid4 available in the Autodock4 suite. Docking of 1364 compounds was performed using Autodock4, the entire process of format conversion of files, preparation of grid and dock parameter files were automated using an in house Perl script. 1 in supplementary material) .
To understand the interaction between β -lactamase and the four compounds from the NCI Diversity Set II, complexes were generated using AutodockTools for outputs of Autodock solutions. LIGPLOT were run for all the four complexes (Figure 3) . It is evident from the analysis of the Docked complex that the Ligands are located in the center of the Active site, and is stabilized by hydrogen bonding
interactions. The interaction analysis shows that Ser 64, Tyr 151 and Thr 317 are important anchoring residues for β -lactamase and the main contributors towards compound interaction. Though the interaction energy does not include the contribution from the water of the extended compound structure, this preliminary data along with the list of hydrogen bond interactions between the compounds and the Active site residues clearly supports that Ser 64, Tyr 151 and Thr 317 are more preferred residues in binding.
Conclusion:
AmpC/β -lactamase is shown to be most potent cause for antimicrobial resistance in Pseudomonas aeruginosa. In this work, predicted 3dimensional Model of AmpC / β -lactamase was used for Virtual Screening of NIC Diversity Set II compounds. Docking results indicate that out of 1364 compounds, there were four inhibitory compounds for AmpC/β-lactamase as target for antimicrobial resistance in Pseudomonas aeruginosa. Hydrogen bonding proved to play an important role for the structure and function of biological molecules, especially for inhibition in a complex. Thus our study confirms that ligand molecules having the following ZINC Ids ZINC12670903, ZINC17465965, ZINC11681166 and ZINC13099024 are potential inhibitor for AmpC / β -lactamase as target for antimicrobial resistance in Pseudomonas aeruginosa. Yet to confirm it to be promising, Pharmacological studies need to be performed.
